LENZ Therapeutics (NASDAQ:LENZ – Get Free Report) is anticipated to announce its earnings results before the market opens on Wednesday, February 26th. Analysts expect the company to announce earnings of ($0.41) per share for the quarter.
LENZ Therapeutics Trading Down 4.1 %
NASDAQ LENZ opened at $22.53 on Tuesday. The business’s 50-day moving average price is $26.38 and its two-hundred day moving average price is $27.00. LENZ Therapeutics has a 12 month low of $14.42 and a 12 month high of $38.93.
Analyst Upgrades and Downgrades
Separately, HC Wainwright reiterated a “buy” rating and issued a $38.00 price target on shares of LENZ Therapeutics in a report on Thursday, November 7th. Six investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Buy” and a consensus target price of $35.40.
LENZ Therapeutics Company Profile
LENZ Therapeutics, Inc, a biopharmaceutical company, focuses on developing and commercializing therapies to improve vision in the United States. Its product candidates include LNZ100 and LNZ101 which are in Phase III clinical trials for the treatment of presbyopia. The company is headquartered in Del Mar, California.
Read More
- Five stocks we like better than LENZ Therapeutics
- Stock Market Sectors: What Are They and How Many Are There?
- Rivian’s Rough Patch: Is the Dip a Doorway to Long-Term Gains?
- What is the Shanghai Stock Exchange Composite Index?
- Institutions Signal Opportunty to Buy High-Yield Kraft-Heinz
- What Investors Need to Know About Upcoming IPOs
- 3 Explosive Tech Stocks Breaking Out Right Now
Receive News & Ratings for LENZ Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LENZ Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
